We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Codexis Enters into Research Collaboration with Schering-Plough

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Codexis, Inc. has announced that it has signed a research agreement with Schering-Plough Corporation to develop a synthetic process for use by Schering-Plough

The collaboration will focus on improving biocatalyst productivity using Codexis' proprietary MolecularBreeding™ pharmaceutical process re-engineering platform.

Codexis will receive research funding and milestone payments upon completion of certain objectives of the research.

"We are pleased to add Schering-Plough to our list of industry-leading pharmaceutical partners," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.

"We are delighted to see a growing number of major pharmaceutical companies recognizing the competitive advantage and cost-savings value that Codexis' technology brings to the manufacturing process for clinical-scale production and product commercialization, and look forward to continued adoption of our technology across the pharmaceutical industry."